Definition · Plain-language
Good Manufacturing Practice (GMP)
Good Manufacturing Practice (GMP), often written as cGMP, is the regulatory framework ensuring medicines and other regulated products are consistently produced and controlled to the quality standards appropriate to their intended use.
The step most authors miss
Doing CRediT right? Don’t stop at the statement.
A CRediT statement credits you inside one paper. The recognition CRediT was built for happens when those roles are tied to you, persistently. Sign in with your ORCID — free — and claim your CRediT contributions on casrai.org, the home of the standard. They become a verified, portable part of your identity, not a line that disappears into one PDF.
Free: claim your contributions, then export a journal-ready CRediT statement, schema.org structured data, JATS XML, CSV or BibTeX — and preview your public profile. A membership publishes that profile publicly and verifies the journals you serve.
What GMP covers
GMP addresses every input and activity that can affect product quality. This includes the suitability of premises and equipment, the qualification of suppliers and raw materials, validated manufacturing processes, calibrated instruments, trained personnel, controlled environments, and complete batch documentation. The guiding idea is that quality cannot be tested into a finished product after the fact — it must be built in through control of the process. GMP therefore emphasises prevention of contamination, mix-ups and errors at every step.
Why the “c” in cGMP matters
In the United States the regulations are commonly called cGMP, where the “c” means “current”. This signals that manufacturers must use up-to-date technologies and systems to comply; a method considered adequate decades ago may no longer meet expectations. The “current” qualifier prevents firms from treating compliance as a fixed checklist and instead requires continual improvement in line with evolving science and engineering. It is a deliberate feature of the FDA framework rather than a minor abbreviation.
The regulatory basis
In the US, GMP for finished pharmaceuticals is set out in 21 CFR Part 211, with Part 210 stating the scope; separate parts cover active ingredients and biologics. The European Union publishes its GMP requirements in EudraLex Volume 4, and the WHO and PIC/S maintain widely adopted GMP guides. Although the documents differ in structure, they converge on the same expectations, and inspection failures can lead to warning letters, import alerts or suspension of a manufacturing licence.
Key facts
At a glance
- Definition: system ensuring products are consistently produced and controlled to quality standards
- Core principle: quality is built into the process, not tested in afterwards
- US regulation: FDA 21 CFR Parts 210 and 211 (finished pharmaceuticals)
- EU basis: EudraLex Volume 4; also WHO and PIC/S GMP guides
- Meaning of “c”: “current” — practices must keep pace with technology
- Enforced by: regulatory inspection; failures can halt manufacture
Common misconceptions
What people often get wrong
Often heard: GMP means you test every finished batch and reject the bad ones.
Actually: GMP is built on the principle that quality must be designed and controlled into the process, not merely tested at the end. Finished-product testing alone cannot guarantee quality, because sampling can miss defects; robust process control and documentation are essential.
Often heard: The “c” in cGMP is just an abbreviation with no real meaning.
Actually: The “c” stands for “current” and is deliberate. It obliges manufacturers to use up-to-date technologies and systems, preventing compliance from becoming a frozen checklist and requiring continual improvement.
Often heard: GMP only applies to the final production line.
Actually: GMP spans the entire manufacturing system — premises, equipment, materials, personnel, hygiene, environmental controls and documentation. Any of these can compromise product quality, so all fall within GMP scope.
Going deeper
